Ignite Creation Date:
2025-12-25 @ 3:53 AM
Ignite Modification Date:
2026-03-03 @ 4:48 PM
Study NCT ID:
NCT02599402
Status:
COMPLETED
Last Update Posted:
2021-06-15
First Post:
2015-11-05
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-12-20
Start Date Type:
ACTUAL
Primary Completion Date:
2020-02-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-02-10
Completion Date Type:
ACTUAL
First Submit Date:
2015-11-05
First Submit QC Date:
None
Study First Post Date:
2015-11-06
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-04-23
Results First Submit QC Date:
None
Results First Post Date:
2021-06-15
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-05-20
Last Update Post Date:
2021-06-15
Last Update Post Date Type:
ACTUAL